Radiopharmaceutical preparation of technetium-99m-labeled galactosyl neoglycoalbumin

David R. Vera, Robert C. Stadalnik, Masatoshi Kudo, Kenneth A. Krohn

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

The principal safety features of an injectable solution are sterility and apyrogenicity. A sterile solution does not contain living organisms; an apyrogenic solution does not contain metabolic products of living organisms or debris of dead organisms which can cause a pyretic response on injection. In humans the pyretic response illicits a sudden onset of chills and fever. The chapter describes a method for the laboratory-scale production of an injectable solution of a radiolabeled neoglycoalbumin. This method is applicable to any radiolabeled macromolecule and is directed toward the academic setting where moderate amounts of injectable material are required for testing “proof-of-principle” or a clinical hypothesis.

Original languageEnglish (US)
Pages (from-to)402-409
Number of pages8
JournalMethods in Enzymology
Volume247
Issue numberC
DOIs
StatePublished - Jan 1 1994

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Fingerprint Dive into the research topics of 'Radiopharmaceutical preparation of technetium-99m-labeled galactosyl neoglycoalbumin'. Together they form a unique fingerprint.

  • Cite this